Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation

Fundamental and Clinical Pharmacology

Volumn 28, Issue 2, 2014, Pages 221-229

  Derosa, Giuseppe ^a   Ragonesi, Pietro Dario ^b   Fogari, Elena ^a   Cicero, Arrigo Francesco Giuseppe ^c   Bianchi, Lucio ^a   Bonaventura, Aldo ^a   Romano, Davide ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

DPP 4 inhibitors; Glycemic control; Insulin resistance; Lipid profile; Sitagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ATORVASTATIN; BIGUANIDE DERIVATIVE; CHOLESTEROL; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE INDEX; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETERS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; YOUNG ADULT;

DPP-4 INHIBITORS; GLYCEMIC CONTROL; INSULIN RESISTANCE; LIPID PROFILE; SITAGLIPTIN;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ITALY; LIPIDS; MALE; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84895529499     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12001     Document Type: Article

References (39)

1. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care (2011) 34 S11-S61.
2. Nathan D.M., Buse J.B., Davidson M.B. et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2009) 52 17-30.
3. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology (2002) 122 531-544.
4. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab. (2004) 287 E199-E206.
5. Drucker D.J., Nauck M.A. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 368 1696-1705.
6. Triplitt C., McGill J.B., Porte D. Jr, Conner C.S. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J. Manag. Care Pharm. (2007) 13 S2-S16.
7. Derosa G., Maffioli P., Salvadeo S.A. et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol. Ther. (2010) 12 233-240.
8. Derosa G., Putignano P., Bossi A.C. et al. Exenatide or glimepiride added to metformin on metabolic control and 3 on insulin resistance in type 2 diabetic patients. Eur. J. Pharmacol. (2011) 666 251-256.
9. Derosa G., Franzetti I.G., Querci F. et al. Exenatide plus metformin compared to metformin alone on β-cell function in patients with type 2 diabetes. Diabet. Med. (2012). doi: 10.1111/j.1464-5491.2012.03699.x.
10. Derosa G., Maffioli P., Salvadeo S.A. et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2010) 59 887-895.
11. Derosa G., Carbone A., Franzetti I. et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract. (2012). doi: 10.1016/j.diabres.2012.05.022
12. Derosa G., Carbone A., D'angelo A. et al. A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin. Pharmacother. (2012). doi:10.1517/14656566.2012.730519.
13. Derosa G., Maffioli P., Ferrari I. et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm. Metab. Res. (2010) 42 663-669.
14. Derosa G., Ragonesi P.D., Carbone A. et al. Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes Technol. Ther. (2012) 14 475-484.
15. Derosa G., Ragonesi P.D., Carbone A. et al. Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study. Expert Opin. Pharmacother. (2012). doi: 10.1517/14656566.2012.734499.
16. Derosa G., Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. (2011) 4 263-271.
17. Derosa G., Maffioli P. DPP-4 inhibitors: three years of experience. Diabetes Technol. Ther. (2012) 14 350-364.
18. Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. (2011) 13 160-168.
19. Rydén L., Standl E., Bartnik M. et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. (2007) 28 88-136.
20. Lichtenstein A.H., Appel L.J., Brands M. et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler. Thromb. Vasc. Biol. (2006) 26 2186-2191.
21. Bunn H.F., Gabbay K.H., Gallop P.M. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science (1978) 200 21-27.
22. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet. Med. (1999) 16 716-730.
23. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia (1972) 8 260-266.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28 412-419.
25. Klose S., Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J. Clin. Chem. Clin. Biochem. (1978) 15 121-130.
26. Wahlefeld A.W. Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis, 2nd English edn. Academic Press, Inc., New York, 1974, pp. 18-31.
27. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. (1955) 34 1345-1353.
28. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin. Chem. (1972) 18 499-502.
29. Winer B.J. Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, 1971.
30. Seck T.L., Engel S.S., Williams-Herman D.E. et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res. Clin. Pract. (2011) 93 e15-e17.
31. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G.; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care (2006) 29 2638-2643.
32. Reynolds J.K. Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. (2009) 2 127-134.
33. Barnard K., Cox M.E., Green J.B. Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. (2010) 3 363-372.
34. Aschner P., Katzeff H.L., Guo H. et al.; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes. Metab. (2010) 12 252-261.
35. Vilsbøll T., Rosenstock J., Yki-Järvinen H. et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. (2010) 12 167-177.
36. Derosa G., Tinelli C., Maffioli P. Effects of pioglitazone, rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes. Metab. (2009) 11 1091-1099.
37. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P.; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes. Metab. (2007) 9 194-205.
38. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P.; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. (2007) 9 733-745.
39. Horton E.S., Silberman C., Davis K.L., Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care (2010) 33 1759-1765.